back to top
Saturday, 15 February, 2025
HomeNews UpdateLilly hopes for 2026 approval for new weight loss pill

Lilly hopes for 2026 approval for new weight loss pill

Eli Lilly expects its experimental weight loss pill – orforglipron – to be approved as early next year, and plans to release key late-stage trial data on the drug by the middle of this year.

Eli Lilly and Novo Nordisk, which dominate the market with their obesity injections Zepbound and Wegovy, respectively, are both looking to develop next-generation versions.

A weight loss pill would offer more convenience to patients and would be easier to manufacture than the jabs.

Eli Lilly is pushing to get the pill to market as it competes with Novo Nordisk and smaller rivals for a major share of the booming weight loss drug market. While their products dominate the space, the drugmakers and their competitors have been working to develop improved versions of the drugs, according to a Bloomberg report in CNBC.

Pills would be more convenient for patients than the current injectable forms, and also easier to manufacture at a time when Eli Lilly and Novo Nordisk have struggled to make enough drugs to keep up with spiking demand.

Eli Lilly has said orforglipron helped patients lose up to 14.7% of their weight in a mid-stage trial, compared with 2.3% among people who took a placebo.

 

CNBC article – Eli Lilly CEO expects new weight loss pill to be approved next year (Open access)

 

See more from MedicalBrief archives:

 

Global race heats up for weight-loss drug pill

 

Novo, Lilly sued by patients for gastroparesis

 

Eli Lilly tightens diabetes drug access, frustrates obese patients

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.